UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2017
Commission File Number:001-38281
ERYTECH Pharma S.A.
(Translation of registrant’s name into English)
Bâtiment Adénine, 60 Avenue Rockefeller
69008 Lyon France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form20-F ☐ Form40-F
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM6-K
ERYTECH Pharma S.A. is submitting this Report on Form6-K to furnish its (i) unaudited interim condensed consolidated statements of financial position as of December 31, 2016 and June 30, 2017 and (ii) unaudited interim condensed consolidated statements of income (loss) for the six months ended June 30, 2016 and 2017, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form6-K.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ERYTECH Pharma S.A. | ||||||
| Date: December 7, 2017 | By: | /s/ Eric Soyer | ||||
| Name Eric Soyer | ||||||
| Title: Chief Financial Officer and Chief Operating Officer | ||||||
